Seock-Ah Im

home / authors / seock-ah-im

Articles

30 Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Previously-Treated Inoperable or Metastatic Hormone Receptor–Positive, HER2-Negative (HR+/HER2–) Breast Cancer (BC): Primary Results From the Randomised Phase 3 TROPION-Breast01 Trial

30 Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Previously-Treated Inoperable or Metastatic Hormone Receptor–Positive, HER2-Negative (HR+/HER2–) Breast Cancer (BC): Primary Results From the Randomised Phase 3 TROPION-Breast01 Trial

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Komal Jhaveri;Seock-Ah Im;Senia Pernas;Michelino De Laurentiis;Shusen Wang;Noelia Martínez Jañez;Giuliano Borges;David W. Cescon;Masaya Hattori;Yen-Shen Lu;Erika P. Hamilton, MD;Qingyuan Zhang;Junji Tsurutani;Kevin Kalinsky, MD, MS;Lu Xu;Neelima Denduluri;Binghe Xu;Barbara Pistilli
July 20th 2024
32 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage Triple- Negative Breast Cancer: Updated Event-Free Survival Results From the Phase 3 KEYNOTE-522 Study

32 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage Triple- Negative Breast Cancer: Updated Event-Free Survival Results From the Phase 3 KEYNOTE-522 Study

Peter Schmid, MD;Javier Cortes;Rebecca Dent, MD;Lajos Pusztai, MD, DPhil;Heather McArthur, MD, MPH;Sherko Kümmel;Carsten Denkert;Yeon Hee Park;Rina Hui;Nadia Harbeck, MD, PhD;Masato Takahashi;Theodoros Foukakis;Marie-Ange Mouret-Reynier;Marta Ferreira;Seock-Ah Im;Fatima Cardoso;Yu Ding;Wilbur Pan;Konstantinos Tryfonidis;Joyce O’Shaughnessy, MD
July 7th 2024
16 Primary Results From the Randomized Phase II RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2− Advanced Breast Cancer Treated With Ribociclib + Endocrine Therapy vs Physician’s Choice Combination Chemotherapy

16 Primary Results From the Randomized Phase II RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2− Advanced Breast Cancer Treated With Ribociclib + Endocrine Therapy vs Physician’s Choice Combination Chemotherapy

Melissa Gao;Yen-Shen Lu;Eznal Izwadi Bin Mohd Mahidin;Hamdy Abdel Azim;Yesim Eralp;Yoon Sim Yap;Seock-Ah Im;Julie Rihani;James Bowles;Teresa Delgar Alfaro;Jiwen Wu;Khemaies Slimane;Nagi El Saghir
April 28th 2023

Latest Updated Articles

OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
45-Year-Old Female With Gross Hematuria Post Partial Nephrectomy
Published: March 1st 2018 | Updated: July 27th 2024
45-Year-Old Female With Gross Hematuria Post Partial Nephrectomy
Neonate With a Soft, Yellowish-Colored Plaque on the Temple
Published: July 16th 2011 | Updated: July 27th 2024
Neonate With a Soft, Yellowish-Colored Plaque on the Temple
A 54-Year-Old Woman Notes the Abundant Development of Nonpigmented Hair on Her Ears and Nose
Published: May 12th 2012 | Updated: July 27th 2024
A 54-Year-Old Woman Notes the Abundant Development of Nonpigmented Hair on Her Ears and Nose
Patient With History of COPD Presents With Abdominal Pain
Published: December 1st 2016 | Updated: July 27th 2024
Patient With History of COPD Presents With Abdominal Pain